Muscle Protein Metabolism in Obesity
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Scottsdale/Phoenix, Arizona: 12-004000
NCT ID: NCT01824173
Sponsor Protocol Number: 12-004000
About this study
Obesity is associated with reduced adenosine triphosphate (ATP) turnover in skeletal muscle, a condition that can impair muscle metabolism. The proposed research will discover mechanisms responsible for decreased content in mitochondrial proteins as well as in protein β-F1-ATPase, which is directly responsible for ATP assembly, in the muscle of obese individuals. This research will further examine the effectiveness of interventions, such as increased plasma amino acid availability and exercise, to increase the rate of production of mitochondrial proteins as well as that of β-F1-ATPase in the muscle of obese individuals. The findings will help to develop appropriate interventions to improve muscle ATP turnover and metabolism in obese people.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion criteria:
- Body mass index (BMI): lean, 19-25 kg/m2; obese, 30-40 kg/m2
- Availability of transportation
- Ability to sign informed consent form
Exclusion criteria:
- Medication or supplements (i.e. amino acids, protein) known to affect protein metabolism
- Presence of acute illness
- History of liver disease
- Uncontrolled metabolic disease
- ECG documented abnormalities, atrial fibrillation, history of syncope, limiting or unstable angina, or congestive heart failure
- Chronically elevated blood pressure (systolic, >140 mmHg; diastolic, >100 mmHg)
- Cardiac pacemaker or other medical device implanted in the body
- Low hemoglobin or hematocrit
- Current participation in a weight-loss regimen, including extreme dietary practices
- Smoking
- Use of anabolic steroids or corticosteroids (within 3 months)
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Scottsdale/Phoenix, Ariz.
Mayo Clinic principal investigator Lori Roust, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available